siRNA–cell-penetrating peptide complexes as a combinatorial therapy against chronic myeloid leukemia (2017)
Sequence: KLFMALVAFLRFLTIPPTAGILKRWGTI
| Experiment Id | EXP000632 |
|---|---|
| Paper | siRNA–cell-penetrating peptide complexes as a combinatorial therapy against chronic myeloid leukemia |
| Peptide | pepM |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 0.5–5 µM |
| Rna Concentration | 16 nM |
| Mixing Ratio | 5:1 (peptide:siRNA) |
| Formulation Format | CPP–siRNA electrostatic complexes |
| Formulation Components | pepM + siRNA |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | BV173 (Ph+ CML cell line) |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown / antiproliferative effect |
| Output Value | Significant Bcr-Abl1 mRNA reduction |
| Output Units | |
| Output Notes | pepM superior to pepR; bioportide anticancer activity |
| Toxicity Notes | No significant toxicity at effective doses |
| Curation Notes |